Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glepaglutide bridging PK trial comparing syringe and autoinjector
NL-OMON49360Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Mar 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glepaglutide in short bowel syndrome (SBS) (3 arms), sponsored by Zealand Pharma. Primary endpoints: Cmax of ZP1848total in plasma and AUC0-t of ZP1848total in plasma. Started Mar 2020; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NL-OMON49360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49360.